CAS: 553-08-2; N-(2-((4-Methoxybenzyl)(Pyrimidin-2-yl)Amino)Ethyl)-N,N-Dimethylhexadecan-1-Aminium Bromide

该化合物是一种四铵化合物,具有表面活性特性,通常用作丙基表面活性剂,以抗微生物和抗食性特性而著称,在各种应用中,包括在个人护理产品,消毒剂和工业配方中具有价值;该化合物的特点是能够减少表面张力,从而提高其在清洁和乳化剂方面的效力;该化合物在水中溶解,可形成稳定的乳胶,有助于其配方的用途;此外,必须谨慎地处理该物质,因为四铵化合物可能对皮肤和眼睛产生刺激性;该物质对广泛种类的微生物的功效使其在旨在控制感染的配方中成为受欢迎的选择;然而,与所有化学物质一样,在使用和处理过程中,应当遵循适当的安全措施和准则.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2012190064-A1
    优先权日:2004-10-01
    标题 :Feeding buffers, systems, and methods for in vitro synthesis of biomolecules
    发明人:KUDLICKI WIESLAW ANTONI; KEPPETIPOLA SHIRANTHI; FLETCHER JULIA; GETBEHEAD ASHLEY ELAINE; KATZEN FEDERICO; VOZZA-BROWN LAURA
    权利人:KUDLICKI WIESLAW ANTONI; KEPPETIPOLA SHIRANTHI; FLETCHER JULIA; GETBEHEAD ASHLEY ELAINE; KATZEN FEDERICO; VOZZA-BROWN LAURA; LIFE TECHNOLOGIES CORP
    摘要:Compositions, methods and kits for in vitro systems for synthesis of biomolecules such as polypeptides, are provided herein. Cell extracts that provide enhanced yields of soluble proteins using in vitro protein synthesis methods are provided. The invention also includes methods for producing high yields of proteins by the addition of a feeding solution that includes amino acids and an energy source to an ongoing in vitro synthesis system. The invention also includes methods of using a high-yield in vitro synthesis system to produce large quantities of proteins with incorporated labeled amino acids for analysis by methods such as by NMR. The invention further includes vectors for enhanced production of proteins from nucleic acid templates using in vitro synthesis systems.

    专利号:WO-2021250635-A1
    优先权日:2020-06-11
    标题:Acid salts of fluoroquinolone carboxylic acid based compositions and methods of making and using the same
    发明人:GHOSH SUMANA; BHATTACHARYYA ANAMIKA; SINGH HIMANSHI; SADHASIVAM SURESH; SINHA MAU; GARG MUKESH KUMAR; GARKHAL KALPNA; KUMAR MUKESH; KHARE PRAGATI; GUPTA SWATI; SENGUPTA SHILADITYA; CHAVDARIAN CHARLES G
    权利人:VYOME THERAPEUTICS INC
    摘要:The present disclosure is in the field of pharmaceutical and chemical sciences. The present disclosure generally relates to the synthesis of therapeutic agents, processes for preparing said agents, compositions comprising said therapeutic agents and their uses. In particular, the disclosure relates to medicinally important acid salts of fluoroquinolone carboxylic acid based chemical molecules [compounds of formula (I)], method of preparing said molecules, compositions thereof, and the use of such molecules as therapeutic agents. The said acid salts of fluoroquinolone carboxylic acid based chemical molecules are useful in treating infections such as ear infections, otitis, otitis media including acute otitis media, recurrent otitis media, otitis media with effusion, chronic otitis media, chronic suppurative otitis media, otitis externa (including acute otitis externa, chronic otitis externa), otitis interna and combinations thereof.

    专利号:US-12344944-B2
    优先权日:2019-06-24
    标题 :Method for HF-free facile and rapid synthesis of MXenes related compounds
    发明人:HAO JIANHUA; PANG SIN YI
    权利人:UNIV HONG KONG POLYTECHNIC
    摘要:Provided herein is a method for preparing MXenes, such as Ti2CTx, Cr2CTx, and V2CTx, products prepared therefrom, and compositions and devices including the same.

    专利号:US-2009209032-A1
    优先权日:2004-10-01
    标 题 :Feeding buffers, systems, and methods for in vitro synthesis of biomolecules

    专利号:EP-1848812-A2
    优先权日:2004-10-01
    标题:Feeding buffers, systems, and methods for in vitro synthesis of biomolecules

    专利号:US-2020399771-A1
    优先权日:2019-06-24
    标 题:Method for hf-free facile and rapid synthesis of mxenes related compounds

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Zhu X, Gao JJ, Landao-Bassonga E, Pavlos NJ, Qin A, Steer JH, Zheng MH, Dong Y, Cheng TS. Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Biochem Pharmacol. 2016 Mar 15;104:118-30. doi: 10.1016/j.bcp.2016.02.013. Epub 2016 Feb 21. 3(5):298-301. doi: 10.1023/A:1016367503669. 11(1):219-236. doi: 10.1039/c8nr05784b.
    4: Simon-Soro A, Kim D, Li Y, Liu Y, Ito T, Sims KR Jr, Benoit DSW, Bittinger K, Koo H. Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes. NPJ Biofilms Microbiomes. 2021 Jan 22;7(1):7. doi: 10.1038/s41522-020-00181-5.
    5: Liu M, Landuyt B, Klaassen H, Geldhof P, Luyten W. Screening of a drug repurposing library with a nematode motility assay identifies promising anthelmintic hits against Cooperia oncophora and other ruminant parasites. Vet Parasitol. 2019 Jan;265:15-18. doi: 10.1016/j.vetpar.2018.11.014. Epub 2018 Dec 7. 287(13):10236-50. doi: 10.1074/jbc.M111.321133. Epub 2012 Jan 3.

    合成参考文献


    参考文献:10.1124/mol.119.115964
    摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知